Abivax S.A. SEC Filings

ABVX NASDAQ

Welcome to our dedicated page for Abivax S.A. SEC filings (Ticker: ABVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Struggling to find the next clinical milestone hidden in Abivax SA’s dense SEC paperwork? Biotech disclosures pack pages of immunology data, cash-runway tables, and dilution scenarios that matter to every ABVX shareholder. Whether you are tracking obefazimod’s Phase III progress or weighing financing risk, the details often sit deep inside a 20-F, a sudden 8-K, or a Form 4 showing an executive stock purchase.

Stock Titan turns those complex documents into clear insights. Our AI-powered summaries translate Abivax’s annual report 10-K simplified explanations, break down each quarterly earnings report 10-Q filing, and flag 8-K material events explained in plain language—minutes after they hit EDGAR. Need real-time alerts on Abivax insider trading Form 4 transactions? You’ll see executive stock transactions Form 4 with context, alongside cash-flow trends and R&D spend extracted automatically. From proxy statement executive compensation tables to shelf-registration details, every filing type is covered and refreshed continuously.

Investors use these distilled insights to: monitor Form 4 insider transactions in real time before key data releases; compare trial-related expenses quarter over quarter; and understand how secondary offerings might affect share count. If you have ever typed “understanding Abivax SEC documents with AI” or “Abivax earnings report filing analysis,” this page is your answer. Access the full library of Abivax SEC filings explained simply, drill into specific numbers with one click, and make decisions backed by complete, up-to-date information—without wading through hundreds of technical pages.

07/23/2025 05:08 PM

Filing

[424B5] Abivax SA American Prospectus Supplement (Debt Securities)

Rhea-AI Summary

DigitalBridge Group, Inc. (DBRG) – Form 4 insider filing

Chief Accounting Officer Tracey Teh reported a single transaction dated 07/21/2025. The issuer withheld 4,079 Class A common shares (code “F”) at $10.76 per share, equal to roughly $43,900, to satisfy payroll-tax obligations triggered by the vesting of a prior equity award. No open-market buy or sell order occurred.

After the withholding, Teh’s direct ownership stands at 64,976 Class A shares. No derivative positions were reported. Because the event reflects routine tax withholding rather than an investment decision, it carries minimal signaling value regarding management’s view of DBRG’s valuation and has no impact on the company’s fundamentals or liquidity.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

586%

[6-K] Abivax SA American Current Report (Foreign Issuer)

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.38%

FAQ

What is the current stock price of Abivax S.A. (ABVX)?

The current stock price of Abivax S.A. (ABVX) is $68.6 as of July 23, 2025.

What is the market cap of Abivax S.A. (ABVX)?

The market cap of Abivax S.A. (ABVX) is approximately 561.7M.

What is Abivax SA's primary focus?

Abivax SA specializes in developing novel therapeutics that harness natural regulatory mechanisms to stabilize the immune response in chronic inflammatory diseases.

Which therapeutic areas does Abivax target?

The company focuses on inflammatory bowel diseases, with a particular emphasis on conditions such as ulcerative colitis, addressing chronic inflammation effectively.

What distinguishes Abivax in the biotech industry?

Abivax differentiates itself by employing advanced immunomodulatory techniques to develop targeted therapies, underpinned by rigorous clinical development and scientific research.

How does Abivax generate value with its business model?

As a clinical-stage entity, Abivax concentrates on advancing its drug candidates through clinical trials, positioning its value on innovative research rather than immediate commercial sales.

Can you explain the significance of obefazimod?

Obefazimod is the company's principal drug candidate, currently in advanced clinical trials. It represents a novel approach in immunomodulatory therapy aimed at managing chronic inflammatory conditions.

How does Abivax build trust in its clinical research?

By following stringent clinical protocols and maintaining transparent data evaluation methods, Abivax ensures its research integrity and fosters confidence among investors and medical professionals.

How does Abivax compare to other biotech companies?

Abivax stands out due to its focused approach on immunomodulation and specific research into inflammatory bowel diseases, giving it a unique position among clinical-stage biotechnology firms.